EE05423B1 - IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon - Google Patents

IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon

Info

Publication number
EE05423B1
EE05423B1 EEP200200463A EEP200200463A EE05423B1 EE 05423 B1 EE05423 B1 EE 05423B1 EE P200200463 A EEP200200463 A EE P200200463A EE P200200463 A EEP200200463 A EE P200200463A EE 05423 B1 EE05423 B1 EE 05423B1
Authority
EE
Estonia
Prior art keywords
inhibitor
manufacture
medicament
prevention
treatment
Prior art date
Application number
EEP200200463A
Other languages
English (en)
Estonian (et)
Inventor
Chvatchko Yolande
Dinarello Charles
Plater-Zyberk Christine
Van Deventer Santer
Rubinstein Menachem
Novick Daniela
Kim Soo-Hyun
Original Assignee
Applied Research Systems Ars Holding N.V.
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Yeda Research And Development Co. Ltd. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200200463A publication Critical patent/EE200200463A/xx
Publication of EE05423B1 publication Critical patent/EE05423B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP200200463A 2000-02-21 2001-02-20 IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon EE05423B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (2)

Publication Number Publication Date
EE200200463A EE200200463A (et) 2003-12-15
EE05423B1 true EE05423B1 (et) 2011-06-15

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200463A EE05423B1 (et) 2000-02-21 2001-02-20 IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon

Country Status (30)

Country Link
US (1) US20030157094A1 (pl)
EP (1) EP1257292B1 (pl)
JP (1) JP4744763B2 (pl)
KR (3) KR20020086540A (pl)
CN (1) CN1322897C (pl)
AT (1) ATE506959T1 (pl)
AU (2) AU4063601A (pl)
BG (1) BG66134B1 (pl)
BR (1) BR0108514A (pl)
CA (2) CA2683009C (pl)
CY (1) CY1111687T1 (pl)
CZ (1) CZ304485B6 (pl)
DE (1) DE60144514D1 (pl)
DK (1) DK1257292T3 (pl)
EA (1) EA005583B1 (pl)
EE (1) EE05423B1 (pl)
HR (1) HRP20020652A2 (pl)
HU (1) HU227752B1 (pl)
IL (2) IL151388A0 (pl)
ME (1) ME00546B (pl)
MX (1) MXPA02008079A (pl)
NO (1) NO331971B1 (pl)
NZ (3) NZ535299A (pl)
PL (1) PL206549B1 (pl)
PT (1) PT1257292E (pl)
RS (1) RS51737B (pl)
SI (1) SI1257292T1 (pl)
SK (1) SK288032B6 (pl)
TR (2) TR200502508T2 (pl)
WO (1) WO2001062285A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
JP2004528010A (ja) 2000-10-11 2004-09-16 バイロン・セラピューティックス・インコーポレーテッド 免疫モジュレーションのための核酸およびポリペプチド
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
EP1425028B1 (en) * 2001-05-16 2009-12-16 Yeda Research And Development Co. Ltd. Use of il-18 inhibitors for the treatement or prevention of sepsis
EP1487457A1 (en) * 2001-11-30 2004-12-22 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2513584A1 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
CA2523912A1 (en) * 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP2177907B1 (en) 2004-06-30 2014-01-01 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use therefor
AU2005264453B2 (en) 2004-07-16 2011-07-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
JP2021527107A (ja) * 2018-06-14 2021-10-11 ユニベルシテ ドゥ ボルドー インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
ATE506959T1 (de) 2011-05-15
US20030157094A1 (en) 2003-08-21
HRP20020652A2 (en) 2004-12-31
IL151388A (en) 2009-09-01
JP4744763B2 (ja) 2011-08-10
CN1404400A (zh) 2003-03-19
CZ304485B6 (cs) 2014-05-28
EE200200463A (et) 2003-12-15
WO2001062285A1 (en) 2001-08-30
NZ520122A (en) 2005-04-29
EP1257292A1 (en) 2002-11-20
NZ535299A (en) 2006-06-30
HU227752B1 (en) 2012-02-28
DE60144514D1 (de) 2011-06-09
AU2001240636B8 (en) 2005-11-03
IL151388A0 (en) 2003-04-10
SI1257292T1 (sl) 2011-08-31
CY1111687T1 (el) 2015-10-07
BG66134B1 (bg) 2011-06-30
CA2399298C (en) 2014-04-15
MXPA02008079A (es) 2003-02-27
CA2399298A1 (en) 2001-08-30
PT1257292E (pt) 2011-07-05
NO331971B1 (no) 2012-05-14
EP1257292B1 (en) 2011-04-27
EA005583B1 (ru) 2005-04-28
KR20020086540A (ko) 2002-11-18
RS51737B (sr) 2011-10-31
TR200202030T2 (tr) 2003-01-21
CZ20022843A3 (cs) 2003-02-12
NZ546294A (en) 2008-02-29
BR0108514A (pt) 2002-12-17
YU60402A (sh) 2005-09-19
PL206549B1 (pl) 2010-08-31
TR200502508T2 (tr) 2007-04-24
DK1257292T3 (da) 2011-07-18
NO20023962L (no) 2002-08-20
CA2683009C (en) 2014-09-23
CA2683009A1 (en) 2001-08-30
HUP0300061A2 (hu) 2003-04-28
HK1051965A1 (en) 2003-08-29
EA200200890A1 (ru) 2003-02-27
KR20070087256A (ko) 2007-08-27
HUP0300061A3 (en) 2005-09-28
SK12082002A3 (sk) 2003-05-02
ME00546B (me) 2011-10-10
JP2003523403A (ja) 2003-08-05
AU4063601A (en) 2001-09-03
NO20023962D0 (no) 2002-08-20
SK288032B6 (sk) 2012-12-03
BG107018A (bg) 2003-09-30
CN1322897C (zh) 2007-06-27
AU2001240636B2 (en) 2005-10-13
KR20070057282A (ko) 2007-06-04
PL357554A1 (pl) 2004-07-26

Similar Documents

Publication Publication Date Title
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
GB0223040D0 (en) Therapeutic compounds
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0008060A (pt) Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
GB0005251D0 (en) Therapeutic compounds
PL369108A1 (pl) Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
BR0312427A (pt) Combinação, uso de uma combinação, método para a produção de um efeito inibitório de ibat em um animal de sangue quente, método de prevenção de diarréia, composição farmacêutica, método de tratamento de condições hiperlipidêmicas em um animal de sangue quente, e, uso de um sal metálico
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
AR034343A1 (es) Combinaciones farmaceuticas
WO2003016563A3 (fr) Cible moleculaire de la neurotoxicite
NO20071399L (no) VLA-4-antagonister
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
SE0001916D0 (sv) Novel formulation
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
WO2003066806A3 (en) Therapeutic use of aziridino compounds
TNSN00242A1 (en) VALDECOXIB COMPOSITIONS

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name